Experienced in Uterine Fibroids

Dr. Christina S. Chu

Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Cooper Gyn Oncology Association PC
2 Cooper Plz, 
Camden, NJ 
Experienced in Uterine Fibroids
Cooper Gyn Oncology Association PC
2 Cooper Plz, 
Camden, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christina Chu is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Camden, New Jersey. Dr. Chu and is rated as an Experienced provider by MediFind in the treatment of Uterine Fibroids. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.

Her clinical research consists of co-authoring 57 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in PA
Hospital Affiliations
Cooper University Hospital
Inspira Medical Center Mullica Hill
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

COOPER GYN ONCOLOGY ASSOCIATION PC
2 Cooper Plz, Camden, NJ 08103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: November 27, 2024
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
View 4 Less Clinical Trials

57 Total Publications

A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery.
A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery.
Journal: Annals of surgery
Published: July 24, 2024
Similar Doctors
Distinguished in Uterine Fibroids
Dr. Norman G. Rosenblum
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Uterine Fibroids
Dr. Norman G. Rosenblum
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Jefferson University Physicians

925 Chestnut St, 
Philadelphia, PA 
 (2.3 mi)
215-955-8874
Languages Spoken:
English
See accepted insurances

Norman Rosenblum is a Gynecologic Oncologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Rosenblum and is rated as a Distinguished provider by MediFind in the treatment of Uterine Fibroids. His top areas of expertise are Endometrial Cancer, Vulvar Cancer, Sertoli-Leydig Cell Tumor, Hysterectomy, and Oophorectomy.

Distinguished in Uterine Fibroids
Dr. Lynda T. Thomas-Mabine
Obstetrics and Gynecology
Distinguished in Uterine Fibroids
Dr. Lynda T. Thomas-Mabine
Obstetrics and Gynecology

Temple Faculty Practice Plan Inc

8815 Germantown Ave, 
Philadelphia, PA 
 (10.8 mi)
215-707-5864
Languages Spoken:
English
See accepted insurances

Lynda Thomas-Mabine is an Obstetrics and Gynecologist in Philadelphia, Pennsylvania. Dr. Thomas-Mabine and is rated as a Distinguished provider by MediFind in the treatment of Uterine Fibroids. Her top areas of expertise are Angiomyoma, Uterine Fibroids, Solitary Fibrous Tumor, and Carney Complex.

Advanced in Uterine Fibroids
Dr. M B. Thomas
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Uterine Fibroids
Dr. M B. Thomas
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Lehigh Valley Physician Group

1627 Chew St, 
Allentown, PA 
 (49.8 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

M Thomas is a Gynecologic Oncologist and an Oncologist in Allentown, Pennsylvania. Dr. Thomas and is rated as a Distinguished provider by MediFind in the treatment of Uterine Fibroids. His top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Ureteroscopy, and Hernia Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chu's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 12 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile